Provided by Tiger Fintech (Singapore) Pte. Ltd.

Redhill Biopharma

1.31
-0.1650-11.19%
Volume:217.83K
Turnover:298.86K
Market Cap:3.01M
PE:-0.20
High:1.51
Open:1.51
Low:1.30
Close:1.48
Loading ...

RedHill Biopharma Rises After Positive FDA Feedback on Crohn's Drug

Dow Jones
·
22 Jul

RedHill Biopharma receives positive FDA feedback for RHB-204 in Crohn’s Disease

TIPRANKS
·
21 Jul

Sector Update: Health Care Stocks Rise in Late Afternoon Trading

MT Newswires Live
·
02 Jul

RedHill Biopharma Launches Phase 2 Clinical Trial for Opaganib/Darolutamide Combination in Advanced Prostate Cancer

Reuters
·
02 Jul

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

PR Newswire
·
02 May

RedHill Biopharma Obtains Allowance for Chinese Patent Application for COVID-19 Treatment

MT Newswires Live
·
29 Apr

RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

PR Newswire
·
28 Apr

RedHill Biopharma Gets Nasdaq Noncompliance Notice

MT Newswires Live
·
18 Apr

RedHill Biopharma receives non-compliance letter from Nasdaq

TIPRANKS
·
18 Apr

RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

PR Newswire
·
18 Apr

RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

PR Newswire
·
16 Apr

Redhill Biopharma FY 2024 EPS $(0.00) Down From $0.01 YoY, Sales $8.04M Up From $6.53M YoY

Benzinga
·
10 Apr

Press Release: RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights

Dow Jones
·
10 Apr

RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum

PR Newswire
·
27 Feb

RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties

PR Newswire
·
25 Feb

RedHill Biopharma Begins Phase 2 Study of Opaganib, Darolutamide for Advanced Prostate Cancer; Shares Rise

MT Newswires Live
·
04 Feb

RedHill Biopharma begins Phase 2 study of prostate cancer combination

TIPRANKS
·
04 Feb

RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer

PR Newswire
·
04 Feb